Qway Research LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,049,604	31
2024	Research	$832,710	42
2023	Research	$812,722	43
2022	Research	$51,686	10
2021	Research	$38,439	21
2020	Research	$15,218	9
2019	Research	$5	1

Breakdown

Who paid Research payments · program years 2019–2025

Sanofi US Services Inc. $1,391,142 28 payments
Pfizer Inc. $728,471 81 payments
Chiesi USA, Inc. $670,835 46 payments
Merck Sharp & Dohme Corporation $9,930 1 payment
Celgene Corporation $5 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma $1,218,255 21 payments
A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study to Evaluate Virological Response and Safety of Oral Pf07817883 in Nonhospitalized Symptomatic Adult Participants With Covid19 $479,204 15 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $314,030 19 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $312,629 14 payments
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 $172,887 7 payments
An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 3Arm Study to Investigate Nirmatrelvirritonavir in Nonhospitalized Participants at Least 12 Years of Age With Symptomatic Covid19 Who Are Immunocompromised $68,517 15 payments
An Interventional Efficacy and Safety Phase 3 Doubleblind 2Arm Study to Investigate Orally Administered Ibuzatrelvir Compared With Placebo in Nonhospitalized Symptomatic Adult and Adolescent Participants With Covid19 Who Are at High Risk of Progressing to Severe Illness $66,000 10 payments
An Interventional Phase 23 Adaptive Multicenter Randomized Doubleblind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared With Placebo in Nonhospitalized Symptomatic Adults With Respiratory Syncytial Virus Infection Who Are at Risk of Progression to Severe Illness $42,213 5 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $41,842 18 payments
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $33,063 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.